<DOC>
	<DOCNO>NCT01611363</DOCNO>
	<brief_summary>In study effect ipragliflozin glucose homeostasis healthy subject T2DM subject , effect exposure ipragliflozin urinary glucose excretion plasma glucose T2DM subject investigate .</brief_summary>
	<brief_title>A Phase 1 Study Investigate Mechanism Action Ipragliflozin</brief_title>
	<detailed_description>This study consist 2 part . In Part A effect ipragliflozin glucose homeostasis investigate Part B investigate effect exposure ipragliflozin UGE plasma glucose level . Part A This part randomize , double-blind , placebo-controlled , 2- period , 2 treatment crossover design healthy subject T2DM subject drug naïve wash metformin prior admission clinical site . Part B This part open-label , randomize , 2-period , 2 treatment crossover design T2DM subject stratify baseline HbA1c level ( 6.0-6.9 % , 7.0-7.9 % , 8.0-8.9 % 9.0-9.9 % ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion Part A : Healthy subject Subject healthy without diabetes mellitus Subject fast plasma glucose ( FPG ) less 5.6 mmol/l screen Subject Body Mass Index ( BMI ) equal 18.5 less 28.0 kg/m2 Subject 's serum creatinine within normal range Inclusion Part A : T2DM subject Subject diagnose T2DM least 6 month Subject 's body mass index ( BMI ) equal 20.0 less 35.0 kg/m2 screen Subject HbA1c level 7.0 % le 9.0 % screening Subject ( FPG ) less 10.0 mmol/l Subject treatment naïve glucoselowering medication use metformin wash least 3 week prior first dose Day 1 Subject 's serum creatinine within normal range Inclusion Part B : T2DM subject Subject body mass index ( BMI ) equal 20.0 less 35.0 kg/m2 screening . Subject diagnose T2DM least 6 month Subject HbA1c level equal 6.0 % le 10 % screen Subject FPG le 10.0 mmol/l Subject drug naïve stable glucose lower therapy ( metformin , TZD , DPP4 inhibitor SUD therapy Exclusion Part A : Healthy subject Any liver function test upper limit normal A QTc interval &gt; 430 m ( male ) &gt; 450 m ( female ) , history unexplained syncope , cardiac arrest , unexplained significant cardiac arrhythmia torsades de pointes , structural heart disease , family history Long QT Syndrome ( LQTS ) Abnormal pulse and/or blood pressure measurement screen follow : Pulse &lt; 40 &gt; 90 bpm ; mean systolic blood pressure &gt; 140 mmHg ; mean diastolic blood pressure &gt; 90 mmHg eGFR ( base Modification Diet Renal Disease ( MDRD ) method ) less 60 ml/min/1.73m2 Day 2 Exclusion Part A &amp; Part B : T2DM subject Subject type 1 diabetes mellitus A QTc interval &gt; 450 m ( male ) &gt; 470 m ( female ) , history unexplained syncope , cardiac arrest , unexplained significant cardiac arrhythmia torsades de pointes , structural heart disease , family history Long QT Syndrome ( LQTS ) Subject insulin therapy receive insulin within 3 month prior screen , exception acute use &lt; 7 day prior screen Subject urinary microalbumin/creatinine ratio equal 300 mg/g screen Subject ALT and/or AST high 3 time upper limit normal total bilirubin 2 time upper limit normal screen Subject symptomatic urinary tract infection symptomatic genitourinary infection screen Subject persistent , uncontrolled severe hypertension indicate mean systolic blood pressure &gt; 160 mmHg mean diastolic blood pressure &gt; 100 mmHg Subject significant cardiovascular disease eGFR ( base MDRD method ) less 60 ml/min/1.73m2 Day 2</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Healthy</keyword>
	<keyword>Ipragliflozin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>